Press Release: Elthera Announces Positive Preclinical Proof of Concept (POC) Studies and Start of New Financing
SCHLIEREN, Switzerland, March 19, 2018 ---Elthera is pleased to announce that it has demonstrated efficacy of its proprietary antibodies in tumor bearing animals. Anne Schmidt, Elthera CEO said, “We are very encouraged by these results demonstrating the efficacy of our antibodies in preclinical models of pancreatic and ovarian carcinomas, both areas where a large unmet medical need remains. These results confirm the multiple publications demonstrating the role of L1CAM in the progression of cancer, and highlight the potential of L1CAM targeting therapies as new treatment for several cancer types expressing L1CAM”. Anne Schmidt also said, “After having successfully raised almost 2 M CHF in 2017, which has enabled us to generate these first POC data, we are now opening the Seed round and we are confident that we will reach our milestone of identifying the clinical candidate by end of 2018”.
Elthera has been selected to be part of the Bilan «50 Swiss start-up in which to invest 2018 »
Elthera wins 3rd prize at the EIT European Health Catapult
The European Health Catapult is a European wide startup competition for early stage startups working in Medtech, Biotech and Digital Health. The participating startups are looking specifically for Seed and Series A investments. The European health Catapult provides investors in early-stage life science companies with an excellent opportunity to gain access to a concentrated elite group of top European startup companies ready to take on a strong partner when they take the first step to economic value creation.